The Structure of Clinical Translation: Efficiency, Information, and Ethics

The last two decades have witnessed a crescendo of allegations that clinical translation is rife with waste and inefficiency. Patient advocates argue that excessively demanding regulations delay access to life-saving drugs, research funders claim that too much basic science languishes in academic la...

Full description

Saved in:  
Bibliographic Details
Authors: Kimmelman, Jonathan (Author) ; London, Alex John (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Published: 2015
In: The Hastings Center report
Year: 2015, Volume: 45, Issue: 2, Pages: 27-39
Online Access: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002c 4500
001 1937533379
003 DE-627
005 20251002055622.0
007 cr uuu---uuuuu
008 251002s2015 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.433  |2 doi 
035 |a (DE-627)1937533379 
035 |a (DE-599)KXP1937533379 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Kimmelman, Jonathan  |e VerfasserIn  |4 aut 
245 1 4 |a The Structure of Clinical Translation: Efficiency, Information, and Ethics 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a The last two decades have witnessed a crescendo of allegations that clinical translation is rife with waste and inefficiency. Patient advocates argue that excessively demanding regulations delay access to life-saving drugs, research funders claim that too much basic science languishes in academic laboratories, journal editors allege that biased reporting squanders public investment in biomedical research, and drug companies (and their critics) argue that far too much is expended in pharmaceutical development. But how should stakeholders evaluate the efficiency of translation and proposed reforms to drug development? Effective reforms require an accurate model of the systems they aspire to improve—their components, their proper functions, and their pathologies. However, there is currently no explicit and well-developed model of translation for evaluating such criticisms. In what follows, we offer an explicit model of clinical translation. Many discussions of clinical translation and its pathologies presume that its main output is tangible: new drugs, vaccines, devices, and diagnostics. We disagree. We argue that the principal output of clinical translation is information—in particular, information about the coordinated set of materials, practices, and constraints needed to safely unlock the therapeutic or preventive activities of drugs, biologics, and diagnostics. To develop this information calls for a process far different from a simple linear progression of clinical trials; it requires exploratory sampling of many different elements in this set. Our model points to some limitations and liabilities of influential proposals for reforming research. It also reveals some underrecognized opportunities for improving the efficiency of clinical translation. 
601 |a Translation 
700 1 |a London, Alex John  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 45(2015), 2, Seite 27-39  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:45  |g year:2015  |g number:2  |g pages:27-39 
856 4 0 |u https://doi.org/10.1002/hast.433  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.433  |x Verlag  |z lizenzpflichtig  |3 Volltext 
912 |a NOMM 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4779659558 
LOK |0 003 DE-627 
LOK |0 004 1937533379 
LOK |0 005 20251002055622 
LOK |0 008 251002||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2025-09-26#078A3F63226EC05CEAE4D0EC90E08C10A40C26EC 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixrk  |a ixzs  |a zota  |a tiep 
ORI |a TA-MARC-ixtheoa001.raw